Pharmacological Activities, Therapeutic Effects, and Mechanistic Actions of Trigonelline

Authors:
Top Cited Papers
Open Access
Publisher website
Google Scholar
Abstract
Trigonelline (TRG) is a natural polar hydrophilic alkaloid that is found in many plants such as green coffee beans and fenugreek seeds. TRG potentially acts on multiple molecular targets, including nuclear factor erythroid 2-related factor 2 (Nrf2), peroxisome proliferator-activated receptor γ, glycogen synthase kinase, tyrosinase, nerve growth factor, estrogen receptor, amyloid-β peptide, and several neurotransmitter receptors. In this review, we systematically summarize the pharmacological activities, medicinal properties, and mechanistic actions of TRG as a potential therapeutic agent. Mechanistically, TRG can facilitate the maintenance and restoration of the metabolic homeostasis of glucose and lipids. It can counteract inflammatory constituents at multiple levels by hampering pro-inflammatory factor release, alleviating inflammatory propagation, and attenuating tissue injury. It concurrently modulates oxidative stress by the blockage of the detrimental Nrf2 pathway when autophagy is impaired. Therefore, it exerts diverse therapeutic effects on a variety of pathological conditions associated with chronic metabolic diseases and age-related disorders. It shows multidimensional effects, including neuroprotection from neurodegenerative disorders and diabetic peripheral neuropathy, neuromodulation, mitigation of cardiovascular disorders, skin diseases, diabetic mellitus, liver and kidney injuries, and anti-pathogen and anti-tumor activities. Further validations are required to define its specific targeting molecules, dissect the underlying mechanistic networks, and corroborate its efficacy in clinical trials.
Funding Information
  • National Institute of Arthritis and Musculoskeletal (R01AR073172, 1R21AR083066, HT9425-23-10008, R01HL160541, R03TR004450)
  • Skin Diseases of the National Institutes of Health (R01AR073172, 1R21AR083066, HT9425-23-10008, R01HL160541, R03TR004450)
  • U.S. Department of War (R01AR073172, 1R21AR083066, HT9425-23-10008, R01HL160541, R03TR004450)
  • National Heart, Lung, and Blood Institute (R01AR073172, 1R21AR083066, HT9425-23-10008, R01HL160541, R03TR004450)
  • National Center for Advancing Translational Science (R01AR073172, 1R21AR083066, HT9425-23-10008, R01HL160541, R03TR004450)

This publication has 121 references indexed in Scilit: